论文部分内容阅读
在由初发同源癌细胞群所制人类子宫内膜癌裸鼠模型上所作研究表明,肿瘤细胞中持续存在孕激素受体(PR)是肿瘤对孕激素治疗产生效应所极为需要的,而且在孕激素持续治疗过积中,PR 的丧失可使初期抑制生长的肿瘤产生抵抗性而再生长。几份研究表明,复发或转移的内膜癌病人中仅20%～25%对孕激素治疗有效应。PR 的存在对提示肿瘤对孕激素治疗的效应有意义。但在临床上,肿瘤对孕激素治疗的效应与生化法测定的 PR 含量间并
Studies performed on a human endometrial cancer nude mouse model made by a population of first-born, homologous cancer cells have shown that the persistence of progestin receptors (PRs) in tumor cells is critically needed for the effect of the tumor on progestin therapy and In the treatment of progesterone overdose, PR loss can make the initial inhibition of growth of tumor resistance and regrowth. Several studies have shown that only 20% -25% of patients with recurrent or metastatic endometrial cancer are effective for progestin therapy. The presence of PR is suggestive of the effect of the tumor on progestin therapy. However, in clinical practice, the effect of the tumor on progestin therapy is correlated with the PR level determined by biochemical methods